Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Enrolling By InvitationNCT06671691
What this trial is testing

A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)SBRT
Universitat de les Illes Balears 15
Large-scale testing (Phase 3)Looking for participantsNCT05212454
What this trial is testing

Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

Who this might be right for
Breast CancerChemotherapy Effect
Second Affiliated Hospital, Zhejiang University, School of Medicine 400
Not applicableLooking for participantsNCT06650423
What this trial is testing

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

Who this might be right for
Early Breast CancerHormone Receptor Positive TumorHER2-negative Breast Cancer
Institute of Oncology Ljubljana 319
Testing effectiveness (Phase 2)Ended earlyNCT05176080
What this trial is testing

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 46
Early research (Phase 1)Looking for participantsNCT06120283
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced Breast CancerMetastatic Breast Cancer+5 more
BeOne Medicines 433
Testing effectiveness (Phase 2)Study completedNCT02520063
What this trial is testing

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Who this might be right for
Breast Cancer
University of Alabama at Birmingham 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105632
What this trial is testing

Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Who this might be right for
Advanced or Metastatic Breast Cancer
Pfizer 333
Not applicableStudy completedNCT03583463
What this trial is testing

ALEXANDRIA Study Egypt

Who this might be right for
Breast Cancer
AstraZeneca 436
Testing effectiveness (Phase 2)Study completedNCT02894398
What this trial is testing

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Who this might be right for
Breast CancerHormone Receptor Positive TumorHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
iOMEDICO AG 388
Large-scale testing (Phase 3)Study completedNCT03969121
What this trial is testing

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Who this might be right for
Breast Cancer FemaleHormone Receptor Positive Malignant Neoplasm of Breast
Kyoto Breast Cancer Research Network 141
Large-scale testing (Phase 3)Study completedNCT02767661
What this trial is testing

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-sen University 263
Not applicableEnrolling By InvitationNCT06791161
What this trial is testing

Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

Who this might be right for
Breast
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 300
Testing effectiveness (Phase 2)Ended earlyNCT02258464
What this trial is testing

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Bayer 99
Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Not applicableLooking for participantsNCT06388122
What this trial is testing

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Who this might be right for
HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast Cancer+6 more
Mayo Clinic 100
Early research (Phase 1)Ended earlyNCT05194072
What this trial is testing

Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms+8 more
Seagen, a wholly owned subsidiary of Pfizer 250
Large-scale testing (Phase 3)Looking for participantsNCT06966700
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Who this might be right for
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC 2,400
Testing effectiveness (Phase 2)Study completedNCT03078751
What this trial is testing

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 54
Large-scale testing (Phase 3)Active Not RecruitingNCT01272037
What this trial is testing

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Who this might be right for
Breast Ductal Carcinoma In SituInvasive Breast CarcinomaMulticentric Breast Carcinoma+2 more
National Cancer Institute (NCI) 5,018
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07658183
What this trial is testing

A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)
Shanghai Best-Link Bioscience, LLC 120
Next Page